NCT06601296View on ClinicalTrials.gov

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Metastatic Renal Cell Carcinoma ( mRCC)OligoProgressive Metastatic Disease
Interventions
DRUG

IMSA101

"All enrolled patients to undergo the following treatment:~SOC treatment: Nivolumab 480 mg monthly PULSAR: 36 Gy in 3 fractions, Q4weeks IMSA101: five intra-tumoral injections of one of the progressive lesions at 1200 mcg (C1D1, C1D8, C1D15, C2D1, C3D1)"

Trial Locations (1)

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER